The 2010s in clinical drug-eluting stent and bioresorbable scaffold research: a Dutch perspective

H. Kawashima · P. Zocca · R. A. Buiten · P. C. Smits · Y. Onuma · J. J. Wykrzykowska · R. J. de Winter · C. von Birgelen · P. W. Serruys

Abstract  Dutch researchers were among the first to perform clinical studies in bare metal coronary stents, the use of which was initially limited by a high incidence of in-stent restenosis. This problem was greatly solved by the introduction of drug-eluting stents (DES). Nevertheless, enthusiasm about first-generation DES was subdued by discussions about a higher risk of very-late stent thrombosis and mortality, which stimulated the development, refinement, and rapid adoption of new DES with more biocompatible durable polymer coatings, biodegradable polymer coatings, or no coating at all. In terms of clinical DES research, the 2010s were characterised by numerous large-scale randomised trials in all-comers and patients with minimal exclusion criteria. Bioresorbable scaffolds (BRS) were developed and investigated. The Igaki-Tamai scaffold without drug elution was clinically tested in the Netherlands in 1999, followed by an everolimus-eluting BRS (Absorb) which showed favourable imaging and clinical results. Afterwards, multiple clinical trials comparing Absorb and its metallic counterpart were performed, revealing an increased rate of scaffold thrombosis during follow-up. Based on these studies, the commercialisation of the device was subsequently halted. Novel technologies are being developed to overcome shortcomings of first-generation BRS. In this narrative review, we look back on numerous devices and on the DES and BRS trials reported by Dutch researchers.

Keywords  All-comer(s) · Bioresorbable scaffold · Drug-eluting stent · Percutaneous coronary intervention · Randomised trial

Introduction

The introduction of bare metal stents (BMS) broadened the options for treating patients with obstructive coronary artery disease, which in the mid-1980s consisted of medical therapy, balloon angioplasty, or bypass surgery [1]. Dutch investigators were among the first to assess the possibilities and limitations of coronary stents [2–4]. A first multicentre study identified early thrombotic stent occlusion as the most important limitation, and it also revealed the problems of restenosis and late stent occlusion [5]. In the 1990s, research went on to refine stents, implantation strategies, and concomitant pharmacological therapy. The BENESTENT-1 and II trials played a pivotal role in establishing coronary stenting as a valuable therapy [6, 7]. Lessons from intravascular ultra-
sound [8] resulted in the use of larger balloon sizes and higher balloon pressures, which optimised stent expansion and apposition, made it possible to simplify the concomitant pharmacological treatment, and profoundly reduced the incidence of stent thrombosis. For many years in-stent re-stenosis was the main limitation of stenting, before the favourable outcome of the durable polymer-coated Cypher sirolimus-eluting stent (SES) in the RAVEL study led to a rapid adoption of the first-generation drug-eluting stents (DES) [9]. Then the early enthusiasm about DES was subdued by discussions about an increased risk of very-late stent thrombosis and mortality [10, 11]. These discussions stimulated the development and rapid implementation of newer-generation DES with refined, more biocompatible coatings during the 2010s. DES research in the 2010s was characterised by numerous large-scale randomised trials in all-comers and patients with minimal exclusion criteria. In addition, bioresorbable scaffolds (BRS) were designed to provide temporary scaffolding and then to disappear later with biodegradation of the device. Igaki-Tamai, the first BRS without drug elution, was implanted in a human in 1999 [12] and demonstrated restenosis rates similar to BMS. In the 2000s, the first and second iteration of an everolimus-eluting BRS were evaluated in the first-in-man studies ABSORB Cohort A and B [13, 14]. The favourable imaging and clinical results of these studies generated enthusiasm for BRS technology. However, the company decided on a worldwide halt to sales of the first-generation Absorb in September 2017 due to a higher rate of major adverse cardiovascular events (MACE) and scaffold thrombosis (ScT), documented in the randomised ABSORB II, III, China, Japan, and AIDA trials [15–18]. To overcome shortcomings of first-generation BRS, new-generation BRS are being developed to improve acute and long-term safety and efficacy.

Scope of this review

In the present narrative review, focused on major randomised DES and BRS trials, we briefly look back on numerous studies that Dutch researchers reported during this decade. In January 2020, we searched on PubMed.gov for clinical studies written in English, published from 1 January 2010 to 31 December 2019, containing the terms “coronary”, and “sten-t” or “scaffold”, and “randomised” in the manuscript title or abstract, containing an abstract, and containing “Netherlands” in the affiliations. We reviewed the summary pages of these manuscripts, searching for first or senior corresponding authors (or principal investigators) affiliated to Dutch medical centres or clinical research organisations. Published abstracts and unpublished oral presentations were not considered. While we aimed at comprehensiveness of major randomised DES and BRS trials reported by Dutch researchers, we cannot exclude that an important study regrettably may not be mentioned.

Assessment of durable polymer DES in myocardial infarction

In the setting of ST-segment elevation myocardial infarction (STEMI), there was little clinical evidence in favour of using DES and even stents in general [19, 20]. Therefore, several randomised trials compared DES versus BMS in this setting. Consecutively, newer-generation DES were compared with first-generation DES. Two trials compared the first-generation Cypher SES with BMS in STEMI patients and reported long-term follow-up data. The DEBATER trial assessed 907 patients and found, at 1 year, that the SES reduced the primary endpoint of major adverse cardiac and cerebrovascular events (16.5% vs. 25.8%, p = 0.001), mainly driven by less repeat revascularisations [21]. After 5 years, the primary endpoint was no longer significantly different (p = 0.12), and the very late (1–5 years) stent thrombosis rates were 2.0% versus 0.7% (p = 0.12) [22]. After 5 years, the MISSION! Intervention study also observed a trend towards more very-late (>1 year) stent thromboses in SES (4.1% vs. 0.7%, p = 0.07) [23]. Two DES trials assessed first-generation Taxus paclitaxel-eluting stents (PES) versus BMS and reported 5-year follow-up [24, 25]. In the PASSION trial, 619 STEMI patients showed no significant between-stent differences.

Dutch contribution to the field

- Dutch researchers reported the first cases and registries of late stent thrombosis of first-generation drug-eluting stents (DES).
- Following the first introduction of the concept of all-comer trials in the LEADERS trial, multiple randomised control trials (RCT) were performed by Dutch leading investigators to compare, in all-comer populations, the first- and second-generation DES or between second-generation DES. These trials have demonstrated the improved outcomes of the second-generation compared with first-generation DES and in general, comparable results between second-generation DES.
- In specific populations, such as ST-segment elevation myocardial infarction and chronic total occlusion, RCT were performed to compare the first- and second-generation DES or between second-generation DES.
- Initial favourable imaging results from the first-in-man trials of the first-generation Absorb led to the wide adoption of the technology of the bioresorbable scaffold. However, the randomised ABSORB II and AIDA trials demonstrated a higher scaffold thrombosis rate and subsequently, the device was withdrawn from the market.
difference in MACE, and there was no significant difference in definite-or-probable stent thrombosis at 5 years [24]. The EXAMINATION trial randomised 1498 STEMI patients to PES or BMS, and after 5 years the rates of the main composite clinical endpoint and of stent thrombosis were comparable for both stents [25]. Notably, in both trials very late stent thrombosis was seen almost exclusively in PES [24, 25].

The newer-generation durable polymer Xience everolimus-eluting stent (EES) was assessed in the XAMI trial, which randomised 625 patients with acute myocardial infarction (MI) to Xience EES or Cypher SES [26]. At 1-year, the rate of MACE was lower in EES (4.0% vs. 7.7%, \( p=0.048 \)), and the definite-or-probable stent thrombosis rates were 1.2 and 2.7% (\( p=0.21 \)) [26]. After 3 years, event rates remained low and similar [27]. The APPENDIX-AMI trial randomised 977 all-comer patients to receive EES or SES, including 112 patients with STEMI, and showed similar 2-year rates of the primary composite endpoint and of stent thrombosis [28]. In a pooled analysis of all patients from XAMI and APPENDIX-AMI, both DES showed similar 2-year outcomes. Moreover, findings were similar in the large subpopulation of STEMI patients [29].

**Evaluation of self-expanding DES in myocardial infarction**

In the setting of acute MI, true vessel size is sometimes underestimated and stents with self-expanding properties may provide theoretical advantages. The APPOSITION II study randomised 80 patients to receive the self-expanding STENTYS SES or BMS. Optical coherence tomography 3 days after stenting showed a lower rate of malapposed stent struts in STENTYS (0.6% vs. 5.5%, \( p<0.001 \)), but clinical outcomes were similar at 6-month follow-up [30]. The APPOSITION IV trial randomised 152 STEMI patients to receive STENTYS SES or Resolute zotarolimus-eluting stents (ZES) and showed with optical coherence tomography that late strut apposition and strut coverage were similar for both devices at 9 months, but achieved earlier in patients treated with STENTYS [31]. A single-centre experience in 120 patients, treated with STENTYS in highly complex coronary lesions and atypical coronary anatomies, revealed reasonable clinical results at 5 years [32].

**Assessment of newer-generation DES in patients with low-to-moderate complexity**

The randomised SPIRIT II and III trials compared Xience EES with first-generation Taxus PES in de-novo lesions. At 2 years, a patient-level pooled analysis in data from 1302 patients found the MACE rate to be significantly lower in EES (7.1% vs. 12.3%, \( p=0.0014 \)) while there was no significant difference in stent thrombosis [33]. At 5-year follow-up of the SPIRIT II trial, which randomised 300 patients to EES or PES, cardiac mortality (1.5% vs. 7.3%, \( p=0.015 \)) and ischaemia-driven MACE (8.0% vs. 18.1%, \( p=0.018 \)) rates were significantly lower in EES, and the stent thrombosis rate was numerically lower in EES (0.9% vs. 2.8%) [34]. A subgroup analysis of the EES group at 3 years showed that treatment of calcified lesions was safe and associated with quite favourable repeat revascularisation rates [35].

Several other newer-generation DES were assessed in small-sized randomised trials with angiographic primary endpoints. The EXCELLA II trial randomised 210 patients to treatment with DESyne novolimus-eluting stents or Endeavor ZES. At 9-month angiographic follow-up, it showed superiority of the DESyne stent in late lumen loss (\( p<0.0001 \)) [36]. After 5 years, patients treated with DESyne showed a significantly lower incidence of device (7.9% vs. 19.7%, \( p=0.022 \)) and patient-oriented events (23.7% vs. 40.8%, \( p=0.016 \)) [37]. In the PIONEER II trial, 170 patients were allocated to implantation of a biodegradable polymer-coated BuMA Supreme SES or Resolute ZES. After 9 months, the angiographic primary non-inferiority endpoint of in-stent late lumen loss was not met, but this result did not translate into impairment in 12-month clinical outcome [38]. The NIREUS trial assessed the BioNIR ridaforolimus-eluting stent and randomised 302 patients to treatment with this device or Resolute Integrity ZES. At 6-month angiographic follow-up, the rates of late lumen loss were similar for both DES (\( p=0.79 \)) [39].

**All-comers trials to assess new durable polymers DES**

In the 2010s, several large-scale randomised trials applied only few exclusion criteria in order to assess newer-generation DES in patient populations that resembled routine clinical practice. The single-centre COMPARE trial assigned 1800 all-comer patients to treatment with Xience EES or Taxus PES and found the 1-year primary composite clinical endpoint to be significantly lower in EES (6.2% vs. 9.1%, \( p=0.02 \)) [40]. In addition, in EES the event rates were lower for stent thrombosis (0.7% vs. 2.5%, \( p=0.002 \)), MI, and target vessel revascularisation [32]. At 5-year follow-up, the early superiority in safety and efficacy of EES over PES was sustained with main endpoint rates of 18.4% versus 25.1% (\( p=0.0005 \)) and definite-or-probable stent thrombosis rates of 3.1% versus 5.9% (\( p=0.005 \)) [41].

Other trials compared two newer-generation DES with each other. In the multicentre Resolve All Comers trial, 2292 all-comer patients were randomised to treatment with Resolute ZES or Xience V EES to compare the device-oriented primary composite clinical endpoint at 1 year [42]. The rates of this endpoint were similar (8.2% vs. 8.3%, \( p=0.92 \)), and there were also no significant between-group differences in secondary endpoints [42]. In patients with bifurcated...
target lesions, treatment with these DES showed favourable results [43]. At the final 5-year follow-up, similar safety and efficacy outcomes were sustained between the two DES [44].

The TWENTE trial assigned 1391 patients (all-comers, except for STEMI) to treatment with Resolute ZES or Xience V EES and showed, after 1 year, a similar incidence of the primary endpoint target vessel failure (8.2% vs. 8.1%, \( p = 0.94 \)) [45]. The single-centre trial enrolled 81.4% of all 1709 eligible patients while the non-enrolled eligible patients were also treated (in a non-randomised fashion) with ZES or EES, showing 1-year outcomes similar to the TWENTE trial participants [46]. After 5 years, TWENTE trial participants showed low and similar stent thrombosis rates for ZES and EES (1.0% vs. 0.6, \( p = 0.37 \)) [47]. Long-term outcomes from the non-enrolled patients supported the validity of these findings [47].

Then, durable polymer DES with more flexible stent designs and/or improved radiographic visibility became available. The DUTCH PEERS (TWENTE II) trial compared the cobalt-chromium Resolute Integrity ZES and the platinum-chromium Promus Element EES in 1811 all-comers, treated at four Dutch centres. The 1-year rate of the primary endpoint target vessel failure was similar for both DES (6.1% vs. 5.2%, \( p = 0.42 \)). Secondary endpoints showed no significant between-DES difference, and longitudinal deformation was only seen in a few patients treated with the angiographically more visible Promus Element EES (1.0% vs. 0%, \( p = 0.002 \)); however, this was not associated with adverse events [48]. Subgroup analyses in patients treated for bifurcation lesions and for MI [49, 50], and the trial’s 5-year follow-up underlined the favourable findings of these two DES [51].

The BIONYX (TWENTE IV) trial investigated the next iteration of the ZES (Resolute Onyx) that uses a newly designed stent, made from a novel swaged shape composite wire and has an outer cobalt-chromium layer with a dense platinum-iridium core, which improves X-ray visibility and allows to slightly reduce strut thickness [52]. The trial randomised 2516 all-comers at 7 centres to treatment with Resolute Onyx ZES versus Orsiro SES and showed, at 1-year follow-up, low and similar rates of the primary endpoint target vessel failure (4.5% vs. 4.7%, \( p = 0.77 \)). In addition, the rates of definite-or-probable stent thrombosis were low (0.1% vs. 0.7%, \( p = 0.011 \)) [52].

### All-comers trials to assess biodegradable polymer DES

DES that leave behind only a bare metal stent after polymer resorption were developed, as theoretically they might improve long-term outcome after stenting. The LEADERS, GLOBAL LEADERS, and COMPARE multicentre trials investigated two types of early-generation biodegradable polymer-coated biolimus A9-eluting stents (BES) with thick stent struts. The LEADERS trial, which randomised 1707 all-comers to treatment with BioMatrix BES versus Cypher SES, had established non-inferiority of the BES at 9 months. At 5-year follow-up, the rate of the main composite clinical endpoint did not differ between DES groups (22.3% vs. 26.1%, \( p = 0.83 \)). But the very-late definite stent thrombosis rate was significantly lower in BES (0.7% vs. 2.5%, \( p = 0.003 \), which corresponded with a significant reduction in thrombosis-associated clinical events [53]. For BES, subgroup analyses at 5-year follow-up suggested a superior long-term efficacy in bifurcated target lesions [54] and better clinical outcomes in MI, especially in patients with STEMI [55]. The GLOBAL LEADERS trial was designed to compare two different antiplatelet regimes in 15,968 patients who were treated with the BioMatrix BES. At 2-year follow-up, the rate of the primary composite endpoint of all-cause mortality and non-fatal MI was low in all patients [56]. In the COMPARE II trial, 2707 patients were assigned to treatment with Nobori BES or durable polymer EES (Xience V, Xience Prime, or Promus). At 1-year follow-up, there was no significant difference in the incidence of the primary composite clinical endpoint which occurred in 5.2% versus 4.8% [57]. Long-term follow-up at 5 years showed that treatment with BES versus EES resulted in main clinical endpoint rates of 15.2% versus 12.9% (\( p = 0.12 \)) and similar combined safety and combined efficacy endpoints. Furthermore, the 5-year definite stent thrombosis rate showed no significant difference between DES groups (1.5% vs. 0.9%; \( p = 0.17 \)) [58]. In patients with diabetes, 5-year event rates were also similar for both DES [59].

Subsequently, biodegradable polymer-coated DES with very thin stent struts were developed. The multicentre BIO-RESORT (TWENTE III) trial randomised 3514 all-comer patients (70% had acute coronary syndromes) to treatment with Synergy EES or Orsiro SES versus durable polymer Resolute Integrity ZES to assess the primary endpoint target failure after 1 year. This endpoint was met in EES by 4.7% and in SES by 4.7% versus 5.4% in ZES (\( p = 0.45 \) and \( p = 0.46 \), respectively). Secondary endpoint rates were also low and similar [60]. At 3-year follow-up, all DES showed similar and favourable medium-term safety and efficacy, and the definite-or-probable stent thrombosis rates were low (1.1, 1.1, and 0.9%) [61]. A subgroup analysis in patients treated in small coronary vessels suggested that the risk of repeated revascularisations may be independently reduced by use of the Orsiro SES (vs. Resolute Integrity ZES, \( p = 0.02 \)) [62].

Meanwhile, other biodegradable polymer-coated DES with very thin stent struts have been developed that also elute sirolimus from their biodegradable polymer coatings. In the multicentre DESSOLVE III trial, 1398 all-comer patients were randomised to implantation of biodegradable polymer MiStent SES or Xience EES. At 1-year follow-up, the device-oriented primary composite clinical endpoint occurred in 5.8%
versus 6.5%, and there was no significant between-DES difference in secondary endpoints [63]. The TAL-ENT trial assessed 1435 all-comer patients at multiple centres, who were assigned to the implantation of biodegradable polymer Supraflex SES or Xience EES. After 1 year, the device-oriented primary composite clinical endpoint was similar in SES and EES (4.9% vs. 5.3%). The incidence of secondary endpoints was low and similar for both devices [64].

**All-comers trial to assess new polymer-free DES**

The polymer-free amphiphilic-eluting stent (PF-AES) releases the antiproliferative drug by means of an amphiphilic polymer, stored in abluminal laser-dug wells [65]. The ReCre8 study randomised a total of 1502 all-comers at three centres to treatment with PF-AES or Resolute Integrity ZES. The primary endpoint occurred in 6.2% versus 5.6% (p=0.67), and there was no difference in secondary endpoints [65].

**Registries assessing endothelial progenitor cell-capturing DES**

Encouraging findings with the Genous endothelial progenitor cell-capturing stent [66–68] resulted in the development of the COMBO stent, which elutes sirolimus from a biodegradable polymer on the abluminal side of the strut and an anti-CD34+ antibody layer on the luminal side to attract circulating endothelial progenitor cells [69]. The REMEDEE registry [70] as well as the COMBO Collaboration [69], which is a patient-level pooled analysis of 3614 patients from the multicentre registries MASCOT and REMEDEE, have shown favourable clinical outcomes after 1 year [69, 70].

**Trials assessing DES in chronic totally occluded coronary arteries**

The PRISON series of randomised clinical trials assessed various coronary DES for treating chronic total occlusion lesions. The PRISON II trial randomised 200 patients to treatment with Cypher SES or BMS and found lower 5-year target vessel revascularisation and MACE rates in SES (p=0.009 and p<0.001) [71]. Furthermore, there was a trend towards more definite stent thromboses in SES. In PRISON III, 304 patients were randomised to receive Cypher SES or ZES (31% Endeavor, 69% Resolute) [72]. The primary angiographic endpoint was in-segment late lumen loss after 8 months, which was lower in SES versus Endeavor ZES (p=0.0002) but not in SES versus Resolute (p=0.58). Three-year follow-up showed a relatively low incidence of adverse events [73]. The PRISON IV trial compared Orsiro SES and Xience EES in 330 patients [74]. The primary non-inferiority endpoint of in-segment late lumen loss at 8 months was not met for the SES vs. EES, and the incidence of binary angiographic restenosis was significantly higher with SES while the stent thrombosis rate was similar [74]. A secondary analysis of this trial suggested that the inferior performance of the SES was pronounced when smaller SES (≤3 mm diameter) were used, which have struts with a thickness of 60 μm [75].

**Trials assessing Absorb BRS**

The everolimus-eluting Absorb scaffold consists of a semi-crystalline poly-L-lactic acid backbone coated with poly-D, L-lactide acid with a strut thickness of 157 μm. The first-in-man trial (ABSORB Cohort A, 30 patients) of the first-generation Absorb demonstrated that after bioresorption of the scaffold, treated coronary arteries had their vasomotion function restored with possible late lumen enlargement [13]. At 5-year follow-up, MACE rate was 3.4% and no ScT was observed [76]. Using the second iteration of the Absorb, the ABSORB Cohort B (101 patients) demonstrated a 5-year MACE rate of 11.0% without any ScT [14]. These results generated enthusiasm for the technology of BRS with the perspective of avoiding the late consequence of a permanent foreign body in the coronary artery.

In the ABSORB II trial, 501 patients with de novo coronary lesions were randomised in a 2:1 ratio to treatment with Absorb or Xience EES [15]. The trial did not show superiority for Absorb with regards to the primary endpoint vasomotor reactivity at 3-year follow-up. In addition, the trial did not meet its co-primary endpoint of non-inferior late lumen loss for the Absorb compared with the EES, which was found to have a significantly lower late luminal loss than the Absorb BRS [77]. In a sub-study, late lumen enlargement and expansive remodelling between the Absorb and the EES were compared [78]. At 3-year follow-up, the relative change in mean vessel area was significantly greater with Absorb compared with the EES (6.7 ± 12.6% vs. 2.9 ± 11.5%, p=0.003); the relative change in mean lumen area was significantly different between the two arms (1.4 ± 19.1% vs. –1.9 ± 10.5%, p=0.031). Definite or probable ScT was more frequently observed in the Absorb group than in the EES group (3.0% vs. 0.0%, p=0.033) [79]. However, between 3 and 5 years, no additional ScT was observed.

In the all-comer AIDA trial [18, 80], 1845 patients undergoing percutaneous coronary intervention were randomised to receive either the Absorb or Xience EES. There was no significant difference in the rate of the primary endpoint target vessel failure. Definite or probable ScT up to 2 years occurred in 31 patients in the Absorb group as compared with 8 patients in the EES group (3.5% vs. 0.9%, p=0.001).

In the ABSORB-STEMI TROFI II trial, 191 patients with STEMI were randomly allocated 1:1 to treatment with the Absorb or Xience Xpedition EES [81]. This trial demonstrated that implantation of culprit lesions with the Absorb in the setting of STEMI resulted in
a nearly complete arterial healing which was comparable with the healing of EES at 6 months.

In the VANISH trial, 60 patients were randomised to treatment with Absorb versus Xience Prime EES and positron emission tomography perfusion imaging was used to assess the effects of both treatments on (hyperaemic) myocardial blood flow and coronary flow reserve over 3-year period [82]. At 1 month, no differences in absolute myocardial perfusion were observed between the two groups. Coronary flow reserve of the treated myocardial territory was significantly lower in patients treated with the Absorb (3.09 ± 0.94 vs. 3.57 ± 0.85, p < 0.05).

In a patient-level meta-analysis of 3389 patients (2164 treated with Absorb vs. 1225 treated with Xience EES) from the randomised trials with patients with chronic coronary syndromes [16, 17, 77, 79, 83, 84], the target lesion failure and ScT rates with the Absorb were significantly higher from 0–3 years compared with the Xience EES (14.9% vs. 11.6%, p = 0.03, and 2.5% vs. 0.8%, p = 0.002, respectively) [85]. However, from 3 to 5 years, the event rates were no longer different between the two devices, and numerically fewer ScT occurred with the Absorb after 3 years. These data imply that the risk period for the Absorb ends at 3 years, suggesting that if improved scaffolds and technique were able to overcome these early risks, the benefits of ‘leaving nothing behind’ might be realised.

The COMPARE ABSORB trial was a prospective, single-blind multicentre trial performed in 45 European sites. The trial was designed to enrol 2100 patients randomised in 1:1 ratio to Absorb or Xience EES [86]. Specific advice on implantation technique including mandatory pre-dilation, sizing, and post-dilation (PSP) was used in the Absorb arm. This trial started with such initial experiences and was one of the first trials with Absorb in which both a specific PSP implantation technique was implemented in the protocol from the start, and that included only experienced operators/centres for enrolment. However, the trial was stopped prematurely by the Data and Safety Monitoring Board in August 2017 based on the results observed in the randomised Absorb trials (ABSORB II, III, China, Japan, and AIDA).

**Other BRS and future development**

Although the first-generation BRS was abandoned in clinical practice based on the outcomes of randomised clinical trials, better outcomes may be obtained with new-generation BRS [87]. The imaging analysis of the Absorb suggested that very late ScT could be attributed to the intra-luminal dismantling caused by the insufficient tissue encapsulation of the strut at long-term follow-up, especially at the period of decreasing mechanical property due to bioresorption [88]. Therefore, new-generation BRS should facilitate the early tissue coverage and late tissue encapsulation of the scaffold strut prior to complete bioresorption of the device. Early embedment and encapsulation could be promoted by a low profile of thin struts with small footprints. Increases in tensile stress of the bioresorbable material with reinforced mechanical properties are an indispensable improvement to achieve that goal. In general, new-generation BRS uses bioresorbable materials with enhanced mechanical properties. ‘STENTiT’ has a unique technological approach to manufacture by electrospinning polymeric tube with microfiber. In a rat model, the implantation of the STENTiT scaffold resulted in the formation of an elastic layer in the endoluminal border: the histomorphological appearance mimics the structure of the internal mammary artery. The other Dutch-based company ‘Xeltis’ is developing bioresorbable devices using supra molecule [89].

**Conclusion**

This review has shed a light on the Dutch contribution to clinical DES and BRS research during the 2010s. During this decade, DES were refined, thoroughly investigated, and rapidly adopted in routine clinical practice. DES research was characterised by a sizeable series of large-scale randomised ‘all-comers’ trials and in patients with minimal exclusion criteria. Most new DES used more biocompatible durable polymer or biodegradable polymer coatings, and there was a trend toward more flexible stent designs and thinner stent struts. During the 2010s, there was a steady decrease in adverse clinical event rates following DES implantation that does not only reflect advances in procedural strategy and concomitant pharmacological treatment, but also refinements in DES technology that were clinically assessed in the trials that we have discussed in this review. The concept of BRS—‘a device that disappears after it has done its job’—is attractive from the viewpoint of the patient. Since the 1990s with the advent of the everolimus-eluting BRS, multiple randomised clinical trials have been performed. However, so far, the device has failed to demonstrate a clinical benefit over the conventional metallic stent. Further development of the bioresorbable technology is expected to overcome the shortcoming of first-generation BRS.

**Conflict of interest** P. Zocca, R.A. Buiten and C. von Birgelen reported institutional research grants from Abbott Vascular, Boston Scientific, Biotronik, and Medtronic to the Research Department of Thoraxcentre Twente, outside the present work. PW. Serruys reports personal fees from Sino Medical Sciences Technology, personal fees from Philips/ Volcano, personal fees from Xeltis, outside the submitted work. H. Kawashima, P.C. Smits, Y. Onuma, J.J. Wykrzykowska and R.J. de Winter reported not to have any relevant conflict of interest.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in
any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless otherwise indicated in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Hugenholtz PG, van den Brand M, Serruys PW, Laird-Meeter K, Bos E. Surgery, angioplasty or drug? Eur Heart J. 1985;6:47–54.
2. Serruys PW, Juilliére Y, Bertrand ME, Puel J, Rickards AF, Sigwart U. Additional improvement of stenosis geometry in human coronary arteries by stenting after balloon dilatation. Am J Cardiol. 1988;61:71G–6G.
3. van der Giessen WJ, Serruys PW, Visser WJ, Verdouw PD, van Schalkwijk WP, Jongkind JE. Endothelialization of intravascular stents. J Interv Cardiol. 1988;1:109–20.
4. Serruys PW, Luijten HE, Beatt KJ, et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation. 1988;77:361–71.
5. Serruys PW, Strauss BH, Beatt KJ, et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med. 1991;324:13–7.
6. Benestent study group, Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489–95.
7. Serruys PW, van Hout B, Bonnier H, et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet. 1998;352:673–81.
8. de Jaegere P, Mudra H, Figulla H, et al. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the multicenter ultrasound stenting in coronaries study (MUSIC study). Eur Heart J. 1998;19:1214–23.
9. RAVEL Study Group (randomized study with the sirolimus-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions), Morice MC, Serruys PW, Sousa JE, et al. Randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–80.
10. Serruys PW, Daemen J. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation. 2007;115:1433–9.
11. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. 2007;115:1440–55.
12. Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000;102:399–404.
13. Serruys PW, Ormiston JA, Onuma Y, et al. Bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373:897–910.
14. Serruys PW, Ormiston J, van Geuns RJ, et al. A polylactide biodegradable scaffold eluting everolimus for treatment of coronary artery disease. Circulation. 2008;117:689–90.
15. Serruys PW, Chevalier B, Dudek D, et al. A bioabsorbable everolimus-eluting scaffold vs. a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385:43–54.
16. ABSORB III Investigators, Ellis SG, Kereiakes DJ, Metzger DC, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373:1905–15.
17. ABSORB Japan Investigators, Kimura T, Kozuma K, Tanabe K, et al. A randomized trial evaluating everolimus-eluting absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015;36:3332–42.
18. AIDA Investigators, A, Wykrzykowska J, Kraa K, Hofma SH, et al. Bioresorbable scaffolds vs. metallic stents in routine PCI. N Engl J Med. 2017;376:2319–28.
19. Suryapranata H, de Luca G, van’t Hof AW, et al. Is routine stenting for acute myocardial infarction superior to balloon angioplasty? A randomised comparison in a large cohort of unsellected patients. Heart. 2005;91:641–5.
20. Laarman G, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting vs. uncoated stents in primary percutaneous coronary intervention. N Engl J Med. 2006;355:1105–13.
21. Wijnsbergen I, Helmes H, Tijssen J, et al. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study. JACC Cardiovasc Interv. 2012;5:313–22.
22. Wijnsbergen I, Tijssen J, Brueren G, et al. Long-term comparison of sirolimus-eluting and bare-metal stents in ST-segment elevation myocardial infarction. Coron Artery Dis. 2014;25:378–83.
23. Boden H, van der Hoeven BL, Liem SS, et al. Five-year clinical follow-up from the MISSION! Intervention study: sirolimus-eluting stent vs. bare metal stent implantation in patients with ST-segment elevation myocardial infarction, a randomised controlled trial. EuroIntervention. 2012;7:1021–9.
24. Vink MA, Dirksen MT, Suttorp MJ, et al. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent vs. a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (paclitaxel-eluting vs. conventional stent in myocardial infarction with ST-segment elevation) trial. JACC Cardiovasc Interv. 2011;4:24–9.
25. Sabaté M, Brugalletta S, Cequier A, et al. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents vs. bare-metal stents (EXAMINATION): 5-year results of a randomised trial. Lancet. 2016;387:357–66.
26. Hofma SH, Brouwer J, Velders MA, et al. Second-generation everolimus-eluting stents vs. first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV stent vs. Cypher stent in primary PCI for acute myocardial infarction) trial. J Am Coll Cardiol. 2012;60:381–7.
27. Hofma SH, Smits PC, Brouwer J, et al. Long-term follow-up of second-generation everolimus-eluting stents vs. first-
The 2010s in clinical drug-eluting stent and bioresorbable scaffold research: a Dutch perspective

Historical Review

50. van Houwelingen KG, Lam MK, Löwik MM, et al. Outcome of specific angiographic indications. Neth Heart J. 2014;22:167–73.

51. van Geuns RJ, Tamburino C, Fajadet J, et al. Self-expanding vs. balloon-expandable stents in acute myocardial infarction: results from the APPPOSITION II study: self-expanding stents in ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2012;5:1209–19.

52. Lu H, Bekker RJ, Grundeken MJ, et al. Five-year clinical follow-up of the STENTYS self-apposing stent in complex coronary anatomy: a single-centre experience with report of specific angiographic indications. Neth Heart J. 2013;21:263–71.

53. Serruys PW, Farooq V, Kalesan B, et al. Improved safety and durability of the novel sirolimus-eluting stent: the PIONEER trial. EuroIntervention. 2018;13:2026–35.

54. Grundeken MJ, Wykrzykowska JJ, Ishibashi Y, et al. First randomised comparison of everolimus-eluting and paclitaxel-eluting stents for coronary revascularization in daily practice: the COMPARE trial (a trial of everolimus-eluting stents and paclitaxel stents for coronary revascularization in daily practice). JACC Cardiovasc Interv. 2015;8:1157–65.

55. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363:136–46.

56. RESOLUTE All Comers Investigators, Diletti R, Garcia-Garcia HM, Bourantas CV, et al. Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial. Heart. 2013;99:1267–74.

57. Iqbal J, Serruys PW, Silber S, et al. Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. Circ Cardiovasc Interv. 2015;8:e2230.

58. vanBirgelen C, Basalasuw,M,Tandjung K, et al. Randomized controlled trial in second-generation zotarolimus-eluting Resolute stents vs. everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol. 2012;59:1350–61.

59. Sen H, Tandjung K, Basalasuw,M, et al. Comparison of eligible non-enrolled patients and the randomised TWENTE trial population treated with Resolute and Xience V drug-eluting stents. EuroIntervention. 2012;8:664–71.

60. von Birgelen C, van der Heijden LC, Basalasuw, M, et al. Five-year outcome after implantation of zotarolimus- and everolimus-eluting stents in randomized trial participants and nonenrolled eligible patients: a secondary analysis of randomized clinical trial. JAMA Cardiol. 2017;2:268–76.

61. von Birgelen C, Sen H, Lam MK, et al. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial. Lancet. 2014;383:413–23.

62. van der Heijden LC, Kok MM, Lam MK, et al. Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial. Clin Res Cardiol. 2016;105:206–15.

63. van Houwelingen KG, Lam MK, Löwik MM, et al. Outcome after myocardial infarction treated with Resolute Integrity and Promus Element stents: insights from the DUTCH PEERS (TWENTE II) randomized trial. Rev Esp Cardiol. 2016;69:1152–9.

64. Zoceca P, Kok MM, Tandjung K, et al. 5-year outcome following randomized treatment of all-comers with zotarolimus-eluting Resolute Integrity and everolimus-eluting PROMUS Element coronary stents: final report of the DUTCH PEERS (TWENTE II) trial. JACC Cardiovasc Interv. 2018;11:1462–9.

65. von Birgelen C, Zoceca P, Buiten RA, et al. Thin composite wire strut, durable polymer-coated (Resolute Onyx) vs. ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomized non-inferiority trial. Lancet. 2018;392:1235–45.

66. Serruys PW, Farooq V, Kalesan B, et al. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents vs. durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (limus eluted from a durable vs. erodable stent coating) randomized, noninferiority trial. JACC Cardiovasc Interv. 2013;6:777–89.

67. Grundeken MJ, Wykrzykowska JJ, Ishibashi Y, et al. First generation vs. second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the LEADERS
all-comers randomized trial. Catheter Cardiovasc Interv. 2016;87:E248–E60.
55. Zhang YJ, Iqbal J, Windecker S, et al. Biolimus-eluting stent with biodegradable polymer improves clinical outcomes in patients with acute myocardial infarction. Heart. 2015;101:271–8.
56. GLOBAL LEADERS investigators, Vranckx P, Valgimigli M, Jüní P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicenter, open-label, randomised superiority trial. Lancet. 2018;392:940–9.
57. Smits PC, Hofma S, Togni M, et al. Abluminal biodegradable polymer biolimus-eluting stent vs. durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet. 2013;381:651–60.
58. Vlachojannis GJ, Smits PC, Hofma SH, et al. Biodegradable polymer biolimus-eluting vs. durable polymer everolimus-eluting stents in patients with coronary artery disease: final 5-year report from the COMPARE II trial (abluminal biodegradable polymer biolimus-eluting stent vs. durable polymer everolimus-eluting stent). JACC Cardiovasc Interv. 2017;10:1215–21.
59. Paradies V, Vlachojannis GJ, Rovaards KJ, Wassing J, van der Est M, Smits PC. Abluminal biodegradable polymer biolimus-eluting stent vs. durable polymer everolimus-eluting stent in patients with diabetes mellitus: 5 years follow-up from the COMPARE II trial. Int J Cardiol. 2019;290:40–4.
60. von Birgelen C, Kok MM, van der Heijden LC, et al. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents vs. durable polymer zotarolimus-eluting stents in all comers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial. Lancet. 2016;388:2607–17.
61. Buiten RA, Ploumen EH, Zocca P, et al. Thin, very thin, or ultrathin strut biodegradable or durable polymer-coated drug-eluting stents: 3-year outcomes of BIO-RESORT. JACC Cardiovasc Interv. 2019;12:1650–60.
62. Buiten RA, Ploumen EH, Zocca P, et al. Outcomes in patients treated with thin-strut, very thin-strut, or ultrathin-strut drug-eluting stents in small coronary vessels: a prespecified analysis of the randomized BIO-RESORT trial. JAMA Cardiol. 2019;4:659–69.
63. de Winter RJ, Katagiri Y, Asano T, et al. A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) vs. an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE II): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial. Lancet. 2018;391:431–40.
64. TALENT trial investigators, Zaman A, de Winter RJ, Kogame N, et al. Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions: a prospective multicentre randomised controlled trial. Lancet. 2019;393:987–97.
65. ReCre8 Study Investigators, Rozemeijer R, Stein M, Voskul M, et al. Randomized all-comers evaluation of a permanent polymer zotarolimus-eluting stent vs. a polymer-free amphimelus-eluting stent. Circulation. 2019;139:67–77.
66. Beijk MA, Klop M, Verouden NJ, et al. Genous endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomised, single-centre, pilot study. Eur Heart J. 2010;31:1053–64.
67. Klop M, Beijk MA, Varma C, et al. 1-year outcome of TRIAS HR (Tri-stent adjudication study high risk of restenosis) a multicenter, randomized trial comparing genous endothelial progenitor cell capturing stents with drug-eluting stents. JACC Cardiovasc Interv. 2011;4:896–904.
68. Woudstra P, Kalkman DN, Beijk MA, et al. Five-year follow-up of the endothelial progenitor cell capturing stent vs. the paclitaxel-eluting stent in de novo coronary lesions with a high risk of coronary restenosis. Catheter Cardiovasc Interv. 2018;91:1212–4.
69. MASCOT: REMEDEE Registry Investigators, de Winter RJ, Chandrasekhar J, Kalkman DN, et al. 1-Year clinical outcomes of all-comers patients treated with the dual-therapy COMBO stent: primary results of the COMBO collaboration. JACC Cardiovasc Interv. 2018;11:1969–78.
70. Woudstra P, Kalkman DN, den Heijer P, et al. 1-Year Results of the REMEDEE Registry: Clinical outcomes after deployment of the abluminal sirolimus-coated bioengineered (Combo) stent in a multicenter, prospective all-comers registry. JACC Cardiovasc Interv. 2016;9:1127–34.
71. van den Branden BJ, Rahel BM, Laarman GJ, et al. Five-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II study). EuroIntervention. 2012;7:1189–96.
72. van den Branden B, Teeuwen K, Koolen J, et al. Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III): a randomised comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions. EuroIntervention. 2013;9:841–53.
73. Teeuwen K, van den Branden BJ, Koolen JJ, et al. Three-year clinical outcome in the primary stenting of totally occluded native coronary arteries III (PRISON III) trial: a randomised comparison between sirolimus-eluting stent implantation and zotarolimus-eluting stent implantation for the treatment of total coronary occlusions. EuroIntervention. 2015;10:1272–5.
74. Teeuwen K, van der Schaaf RJ, Adriaenssens T, et al. Randomized multicenter trial investigating angiographic outcomes of hybrid sirolimus-eluting stents with biodegradable polymer compared with everolimus-eluting stents with durable polymer in chronic total occlusions: the PRISON IV trial. JACC Cardiovasc Interv. 2017;10:133–43.
75. Zivelonghi C, Teeuwen K, Agostoni P, et al. Impact of ultra-thin struts on restenosis after chronic total occlusion recanalization: Insights from the randomized PRISON IV trial. J Interv Cardiol. 2018;31:580–7.
76. Onuma Y, Dudek D, Thuesen L, et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv. 2013;6:999–1009.
77. Serruyts PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016;388:2479–91.
78. Serruyts PW, Katagiri Y, Sotomi Y, et al. Arterial remodeling after bioresorbable scaffolds and metallic stents. J Am Coll Cardiol. 2017;70:60–74.
79. Chevalier B, Cequier A, Dudek D, et al. Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II) trial. EuroIntervention. 2018;13:1561–4.
80. Tijssen RYG, Kraak RP, Hofma SH, et al. Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI. EuroIntervention. 2018;14:e426–e33.
81. Sabate M, Windecker S, Iniguez A, et al. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J. 2016;37:229–40.
82. Stuijfzand WJ, Raijmakers PG, Driessen RS, et al. Evaluation of myocardial blood flow and coronary flow reserve after implantation of a bioresorbable vascular scaffold vs. metal drug-eluting stent: an interim one-month analysis of the VANISH trial. EuroIntervention. 2016;12:e584–e94.
83. ABSORB China Investigators, Gao R, Yang Y, Han Y, et al. Bioresorbable vascular scaffolds vs. metallic stents in patients with coronary artery disease: ABSORB China Trial. J Am Coll Cardiol. 2015;66:2298–309.
84. Onuma Y, Sotomi Y, Shiomi H, et al. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: Insights from the randomised ABSORB Japan trial. EuroIntervention. 2016;12:1090–101.
85. Stone GW, Kimura T, Gao R, et al. Time-varying outcomes with the Absorb bioresorbable vascular scaffold during 5-year follow-up: a systematic meta-analysis and individual patient data pooled study. JAMA Cardiol. 2019; https://doi.org/10.1001/jamacardio.2019.4101.
86. Chang CC, Onuma Y, Achenbach S, et al. COMPARE ABSORB trial investigators. Absorb bioresorbable scaffold vs. Xience metallic stent for prevention of restenosis following percutaneous coronary intervention in patients at high risk of restenosis: rationale and design of the COMPARE ABSORB trial. Cardiovasc Revasc Med. 2019;20:577–82.
87. Katagiri Y, Serruys PW, Asano T, et al. How does the failure of Absorb apply to the other bioresorbable scaffolds? An expert review of first-in-man and pivotal trials. EuroIntervention. 2019;15:116–23.
88. Onuma Y, Honda Y, Asano T, et al. Randomized comparison between everolimus-eluting bioresorbable scaffold and metallic stent: multimodality imaging through 3 years. JACC Cardiovasc Interv. 2020;13:116–27.
89. Kluin J, Talacua H, Smits AI, et al. In situ heart valve tissue engineering using a bioresorbable elastomeric implant—From material design to 12 months follow-up in sheep. Biomaterials. 2017;125:101–17.